Company: IMCR
Filing Date: 2025-03-24
Form Type: PRE 14A
Source: 0001140361-25-010035
Chunk: 117

Company: Immunocore Holdings plc
Filing Date: 2025-03-24
Form: PRE 14A
Chunk 117
---
 the year were made up of Non-Executive Directors and included observers and representatives from the Company’s major shareholders. Kristine Peterson chaired the Committee and Professor Sir John Bell, Siddharth Kaul, Dr Roy S Herbst and Travis Coy were members of the Committee throughout 2024. Ranjeev Krishana was previously an observer on the committee and was appointed as a Non-Executive Director to the Board and as a member of the Committee on 28 May 2024. No conflicts of interest have arisen during the period and none of the members of the Committee has any personal financial interest in the matters discussed, other than as shareholders. The fees of the Non-Executive Directors are approved by the Board on the recommendation of the Committee.

A-15

TABLE OF CONTENTS

During the reporting period, the Committee met six times formally. Details of attendees are as below. Meetings Attendance Attendance

| Kristine Peterson       |     | 6 of 6 |
| Professor Sir John Bell |     | 6 of 6 |
| Travis Coy              |     | 6 of 6 |
| Siddharth Kaul          |     | 6 of 6 |
| Roy Herbst, M.D, Ph.D.  |     | 3 of 6 |
| Ranjeev Krishana        |     | 3 of 6 |

The CEO is invited to attend meetings where appropriate. No individual is present when matters relating to their own remuneration are discussed. Advisors to the Remuneration Committee From 2021, following a competitive tender process, and until 15 September 2023, the Committee had engaged Willis Towers Watson as independent advisors to the Committee to provide independent advice and consultation with respect to remuneration arrangements for the CEO (being our sole Executive Director), non-executive directors, and senior management. Willis Towers Watson is a global remuneration consultant with a well-established reputation for the design and implementation of remuneration programmes, including the design and implementation of equity-based incentive programmes. From 15 September 2023, following a request for proposal (RFP) process, Aon Human Capital Solutions practice, a division of Aon plc (“Aon”) replaced Willis Towers Watson in their role as independent advisors to the Committee. Aon is a global remuneration consultant which delivers compensation insights through data, analytics and advice to help make better and more equitable rewards decisions. This includes compensation and benefits benchmarking and the design of executive, and employee compensation plans. The Committee is satisfied that